丹诺医药冲刺IPO，核心产品临近上市

Core Viewpoint - Danuo Pharmaceutical (Suzhou) Co., Ltd. has submitted an application for a mainboard listing on the Hong Kong Stock Exchange, with CITIC Securities and Agricultural Bank of China International as joint sponsors. The company has incurred a cumulative loss of 453 million yuan over the past two years and is in the commercialization phase for its flagship product, which is expected to be approved for market launch by the end of 2026, with a current valuation of approximately 2.013 billion yuan [1][2]. Company Overview - Founded in 2013, Danuo Pharmaceutical is a biotechnology company focused on discovering, developing, and commercializing differentiated innovative drug products to address unmet clinical needs in bacterial infections and related diseases [2]. - As of January 24, Danuo Pharmaceutical has seven innovative projects, with two core products: TNP-2198 (Rifaterinazole) and TNP-2092 (Rifofloxacin injection) [2]. Product Pipeline - TNP-2198 is the first and only new molecular entity candidate drug for treating Helicobacter pylori infection since its discovery in 1982. It is used in combination with Amoxicillin and PPI in both China and the U.S. for treating Helicobacter pylori infections, and it is also indicated for bacterial vaginosis and Clostridium difficile infections in China. The drug has entered the New Drug Application (NDA) stage with the National Medical Products Administration (NMPA) and is expected to be approved by the end of 2026 [2]. - TNP-2092 is a candidate drug targeting three pathways for treating implant-related bacterial infections, including artificial joint infections and infections related to left ventricular assist devices and central venous catheters in both China and the U.S. It has received Investigational New Drug (IND) approval from both the NMPA and the FDA [2]. Financial Performance - Danuo Pharmaceutical has not generated any revenue in the first three quarters of 2023, 2024, and 2025, with net losses of 192 million yuan, 146 million yuan, and 115 million yuan, respectively, totaling a cumulative loss of 453 million yuan. Research and development expenditures during the same period were 108 million yuan, 69.83 million yuan, and 46.39 million yuan [3]. Valuation and Shareholding - As of January 24, Cumbre entities are the largest single shareholder group of Danuo Pharmaceutical, holding approximately 18.82% of the voting rights. The founder and CEO, Ma Zhenkun, along with the Employee Stock Ownership Plan (ESOP) platform, controls about 13.61% of the voting rights [4]. - Danuo Pharmaceutical has completed seven rounds of equity financing since its establishment, with the latest E round in July 2025, resulting in a post-investment valuation of approximately 2.013 billion yuan [6].